TASLY PHARMACEUTICAL GROUP CO., LTD.
|TASLY PHARMACEUTICAL GROUP CO., LTD. Patent applications|
|Patent application number||Title||Published|
|20130209590||USE OF A CHINESE MEDICINE COMPOSITION IN PREPARING MEDICAMENTS FOR TREATING SECONDARY PREVENTION OF MYOCARDIAL INFARCTION - The present invention relates to a use of Chinese medicine composition in preparation of medicine for secondary prevention of myocardial infarction. Said Chinese medicine composition is prepared from a formula comprising the crude drugs by the following weight percentages: Radix Astragali 22.2%˜66.8%, Radix Salviae Miltiorrhizae 11.6%˜33.4%, Radix Notoginseng 2.5%˜13.5%, and Lignum Dalbergiae Odoriferae 14.5%˜44.3%.||08-15-2013|
|20130196005||USE OF SALVIA MILTIORRHIZA COMPOSITION IN PREPARING DRUGS FOR SECONDARY PREVENTION OF CORONARY HEART DISEASE - Provided is the use of a||08-01-2013|
|20130178516||EXTRACTS OF CHENOPODIUM AMBROSIOIDES L., THE COMPOSITIONS COMPRISING SAID EXTRACTS, THE PREPARING PROCESS AND APPLICATION THEREOF - The present invention relates to plant extracts, specifically, the extracts of Chinese medicine||07-11-2013|
|20120315328||CAPSULE OF COMPOUND DANSHEN DRIPPING PILLS - A capsule of compound danshen dripping pills are disclosed. The color of the capsule's shell is orange, yellow, green or blue and all of these colors are in the wavelength range of 446-620 nm.||12-13-2012|
|20120251634||TRADITIONAL CHINESE DRUG COMPRISING DANSHEN EXTRACTS AND SANQI EXTRACTS AND USE THEREOF - The present invention discloses a traditional Chinese drug consisting of Danshen extract and Sanqi extract, the pharmaceutical composition comprising the above traditional Chinese drug as an active component and the use thereof. The traditional Chinese drug consists of Danshen extract and Sanqi extract in a weight ratio of (2˜6):(0.5˜2). The invention further discloses the effect of the above traditional Chinese drug and the pharmaceutical composition comprising the above traditional Chinese drug as an active component for treating cardiac microcirculation disorder and myocardial damage induced by ischemia/reperfusion.||10-04-2012|
Patent applications by TASLY PHARMACEUTICAL GROUP CO., LTD.